Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by grumpymonkey007on Nov 12, 2013 5:58pm

467 Views

Post# 21899429

992 All in sustaining costs in Q3

Third Quarter 2013 Financial Highlights

Sold 28,344 ounces of gold, a 49% increase over Q3 2012
Cash costs of $617 and All in Sustaining Costs (AISC) of $992 per ounce of gold sold
Made long-term debt repayments of $4.9 million
Revenue of $36.9 million, a 22% increase over Q3 2012
Adjusted cash flow from operations of $15.5 million, a 38% increase over Q3 2012

Third Quarter 2013 Operational Highlights

Produced 27,174 ounces of gold, a 39% increase over Q3 2012
Processed 207,559 tonnes of ore (2,256 tonnes per day) at 4.34 grams per tonne and a 94% recovery
Averaged 811 tonnes per day from underground at an average grade of 5.69 grams per tonne

Bullboard Posts

Gold Flora's Gramlin holds court in California cannabis market